Pharmaceutical News

RSS

Experts provide suggestions to prevent neurological injuries associated with epidural steroid injections

Epidural steroid injections are commonly used to treat pain; however, they can in rare situations produce life-threatening neurological injuries such as stroke and paralysis. In the Online First edition of February's Anesthesiology, the official medical journal of the American Society of Anesthesiologists, a panel of experts representing 13 national medical organizations provided 17 suggestions aimed at preventing such injuries and improving patient safety.

16 Feb 2015

Hospira announces launch of first biosimilar monoclonal antibody in Europe

Hospira, Inc., a world leader in the development of biosimilar therapies, today announced the launch of the first biosimilar monoclonal antibody (mAb), Inflectra (infliximab), in major European markets.

16 Feb 2015

AARDA releases white paper to educate its members, patient community about biosimilar medicines

The American Autoimmune Related Diseases Association, a national nonprofit health organization dedicated to increasing awareness of autoimmune diseases, today issued a white paper to educate its membership and the patient community about biosimilar medicines after a survey found most patients were generally unaware of this new category of medicines which may soon be approved in the U.S.

16 Feb 2015

Increasing opioid doses to manage chronic pain may intensify depression

Patients who increased doses of opioid medicines to manage chronic pain were more likely to experience an increase in depression, according to Saint Louis University findings in Pain.

16 Feb 2015

Novartis receives priority review status from FDA for heart failure medicine LCZ696

Novartis announced today that the US Food and Drug Administration has granted priority review for LCZ696, an investigational medicine for the treatment of heart failure with reduced ejection fraction (HFrEF). The designation is intended to accelerate the review of therapies that offer a significant improvement in the safety or effectiveness of the treatment, prevention or diagnosis of a serious condition.

16 Feb 2015

Experts discuss therapeutic potential of medical cannabis in a symposium organized by MUHC

While debate about recreational marijuana use continues, researchers are investigating the effectiveness of cannabis for treating pain, spasticity, and a host of other medical problems. In a symposium organized by the McGill University Health Centre as part of the 2015 American Association for the Advancement of Science Annual Meeting held this week in San Jose, California, world-renowned experts from North America and the U.K. share their perspectives on the therapeutic potential of medical cannabis and explore the emerging science behind it.

16 Feb 2015

Cervarix effective against other common cancer-causing HPVs

According to a multinational clinical trial involving nearly 20,000 young women, the human papilloma virus vaccine, Cervarix, not only has the potential to prevent cervical cancer, but was effective against other common cancer-causing human papillomaviruses, aside from just the two HPV types, 16 and 18, which are responsible for about 70 percent of all cases.

15 Feb 2015

New antibody shows promise in increasing survival for patients suffering from influenza, pneumonia

Scientists from NTU Singapore, the world's No. 1 young university, have developed an antibody which boosts the survival chances for patients suffering from influenza and pneumonia.

14 Feb 2015

$Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC$

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Eisai Inc. announced today that the U.S. Food and Drug Administration approved the company's receptor tyrosine kinase inhibitor LENVIMA (lenvatinib) for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC).

13 Feb 2015

Actavis releases generic version of Pulmicort RESPULES

Actavis plc today announced that it has launched its generic version of AstraZeneca's Pulmicort RESPULES® (budesonide inhalation suspension) 0.25 and 0.5 mg vials following a ruling from the United States District Court for the District of New Jersey that (i) United States Patent No. 7,524,834 is invalid, and (ii) AstraZeneca's request for a permanent injunction is denied.

13 Feb 2015

Adolescents meth abusers suffer greater alterations in their brain than adult drug abusers

Adolescents who chronically use methamphetamine suffer greater and more widespread alterations in their brain than adults who chronically abuse the drug-and damage is particularly evident in a part of the brain believed to control the "executive function," researchers from the University of Utah and South Korea report.

13 Feb 2015

Health Canada to review Cipher’s self-adhesive medicated plaster, Beteflam Patch

Cipher Pharmaceuticals Inc. (NASDAQ: CPHR; TSX:CPH) ("Cipher" or "the Company") today announced that the Beteflam Patch (previously called the Betesil® Patch) has been accepted for review by Health Canada.

13 Feb 2015

InterveXion receives federal grants for development of drug therapies to treat methamphetamine users

A University of Arkansas for Medical Sciences BioVentures startup company, InterveXion Therapeutics LLC, has received two federal grants totaling $14.5 million for development of drug therapies that can help methamphetamine drug abusers break their addiction.

12 Feb 2015

Specific combinations of therapies kill cancer cells, reduce tumors

Controlling the time and sequence of cancer therapies may hold the key to unlocking better outcomes for patients with aggressive cancers, according to research published today.

12 Feb 2015

Diabetes medication can help white blood cells fight bacterial infections

Pioglitazone, a medication approved for treatment of type 2 diabetes, can help bypass genetic defects in chronic granulomatous disease to help white blood cells fight bacterial infections, according to researchers at National Jewish Health.

12 Feb 2015

Retigabine drug shows promise in protecting the brain against effects of ischemic stroke

Retigabine, a drug approved to treat epilepsy, protected the brain against the effects of ischemic stroke in a study conducted at The University of Texas Health Science Center at San Antonio.

12 Feb 2015

Opioid withdrawal in Ontario newborns increases 15-fold

The number of newborns suffering from opioid withdrawal increased 15-fold in Ontario over 20 years, according to research published today in CMAJ Open.

12 Feb 2015

TINA.org objects to proposed class-action settlement regarding Wellesse glucosamine supplement

Continuing its efforts to fight for settlements that are fair to consumers and mandate real changes in deceptive marketing, advocacy group truthinadvertising.org (TINA.org) has filed an objection in a proposed class-action settlement involving the brand-name glucosamine supplement, Wellesse®. Sold at retailers nationwide, the supplement is advertised as a joint pain remedy to ease pain and even rebuild cartilage.

12 Feb 2015

NanoSmart's ANA-conjugated liposomal doxorubicin receives FDA Orphan Drug Designation

NanoSmart Pharmaceuticals, Inc., a private pharmaceutical company developing nanoparticle drug delivery platforms, has received Orphan Drug Designation from the Food and Drug Administration for one of its lead candidates, antinuclear antibody (ANA) conjugated liposomal doxorubicin.

11 Feb 2015

FDA advisory committees to review Amgen's talimogene laherparepvec for metastatic melanoma treatment

Amgen announced today that the Cellular, Tissue and Gene Therapies Advisory Committee and the Oncologic Drugs Advisory Committee of the U.S. Food and Drug Administration will jointly review the Company's Biologics License Application (BLA) for talimogene laherparepvec.

11 Feb 2015

Pharmaceutical News

Experts provide suggestions to prevent neurological injuries associated with epidural steroid injections

Hospira announces launch of first biosimilar monoclonal antibody in Europe

AARDA releases white paper to educate its members, patient community about biosimilar medicines

Increasing opioid doses to manage chronic pain may intensify depression

Novartis receives priority review status from FDA for heart failure medicine LCZ696

Experts discuss therapeutic potential of medical cannabis in a symposium organized by MUHC

Cervarix effective against other common cancer-causing HPVs

New antibody shows promise in increasing survival for patients suffering from influenza, pneumonia

Eisai announces FDA approval of LENVIMA (lenvatinib) for treatment of RAI-refractory DTC

Actavis releases generic version of Pulmicort RESPULES

Adolescents meth abusers suffer greater alterations in their brain than adult drug abusers

Health Canada to review Cipher’s self-adhesive medicated plaster, Beteflam Patch

InterveXion receives federal grants for development of drug therapies to treat methamphetamine users

Specific combinations of therapies kill cancer cells, reduce tumors

Diabetes medication can help white blood cells fight bacterial infections

Retigabine drug shows promise in protecting the brain against effects of ischemic stroke

Opioid withdrawal in Ontario newborns increases 15-fold

TINA.org objects to proposed class-action settlement regarding Wellesse glucosamine supplement

NanoSmart's ANA-conjugated liposomal doxorubicin receives FDA Orphan Drug Designation

FDA advisory committees to review Amgen's talimogene laherparepvec for metastatic melanoma treatment

How GLP‑1 Agonists Are Shaping the Future of Obesity Treatment With Dr Bryony Henderson

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Latest News